A Study of HS-20110 in Participants With Advanced Solid Tumors

Phase 1

Recruiting

• Conditions: Solid Tumors
• Interventions: Drug: HS-20110 (Phase Ia：Dose escalation )

• Registration Number: NCT06892379
• Lead Sponsor: Hansoh BioMedical R&D Company

Brief Summary

This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-02-24
• Study Start: 2025-02-26
• Study First Submitted QC: 2025-03-18
• Study First Posted: 2025-03-24
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-08
• Last Update Posted: 2025-07-11
• Primary Completion: 2026-12-31
• Study Completion: 2027-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 475

Inclusion Criteria

1. Males or females, aged ≥ 18 years.
2. Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors.
3. Participants have at least 1 target lesion other than CNS lesions according to RECIST 1.1.

Exclusion Criteria

1. Participants have received or are receiving the following treatment:

   1. Drug therapy targeting CDH17 (such as small molecule targeted drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, or chimeric antigen receptor T cells).
   2. Anti-tumor drugs within 14 days prior to the first dose of study treatment; any other IMPs or macromolecular anti-tumor drugs within 28 days prior to the first dose of study treatment.
   3. Local radiotherapy within 2 weeks prior to the first dose of study treatment; irradiation of more than 30% of bone marrow or extensive radiotherapy within 4 weeks prior to the first dose of study treatment.
   4. Major surgery within 4 weeks prior to the first dose of study treatment.
   5. Participants previously treated with drugs that are moderate to strong inhibitors or moderate to strong inducers of cytochrome P450 (CYP) 3A4, strong inhibitors or strong inducers of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) or drugs with a narrow therapeutic range that are sensitive substrates of P-gp or BCRP within 7 days prior to the first dose of the IMP. Participants who need to receive these drugs during the study period should also be excluded.
   6. Current use of drugs known to prolong the QT interval or that may cause torsade de pointes. Participants who need to receive these drugs during the study period should also be excluded.
   7. Live vaccine or live-attenuated vaccine within 28 weeks prior to the first dose.

2. Participants who have any Grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior therapies (except alopecia and residual neurotoxicity).

3. Inadequate bone marrow reserve or hepatic and renal functions.

4. Participants with a history of severe allergy (such as anaphylactic shock), previous severe infusion reactions, or allergy to recombinant human or murine proteins.

5. Participants who are allergic to any component of HS-20110.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
HS-20110 (Phase Ia：Dose escalation )	HS-20110 (Phase Ia：Dose escalation )	-

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose (MTD) or maximum applicable dose (MAD)	From day 1 to one months after the last dose in Phase 1a
Objective response rate (ORR) as per RECIST v1.1	From screening to 2 months after the last dose

Secondary Outcome Measures

Name	Time	Method
Incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose modification or permanent discontinuation, and specific laboratory abnormalities	From the first dose until 90 days after the last dose
Drug concentrations of the three components of HS-20110 (including antibody-drug conjugates, total antibody, and payload)	From the first dose until 90 days after the last dose
Objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; overall survival (OS)	From screening to up to 3 years after last dose
Incidence of anti-HS-20110 antibody (ADA)	From the first dose until 90 days after the last dose

Trial Locations

Locations (3)

BRCR Medical Center INC; 🇺🇸 Tamarac, Florida, United States

The University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

SUN YAT-SEN University Cancer Center; 🇨🇳 Guangzhou, Guangdong, China